Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet and Paclitaxel in Metastatic Breast Cancer
NCT00691912Phase 2Terminated
- Start
- Dec 2006
- Primary completion
- Dec 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in breast cancer. Primary endpoint: Progression Free Survival at 18 weeks. Started Dec 2006; status: terminated.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00691912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00691912.